European Medicines Agency Recommends Rasonque for Metastatic Pancreatic Cancer

The European Medicines Agency's (EMA) human medicines committee (CHMP) has recommended marketing authorization for Rasonque (daraxonrasib). This oral treatment is intended for adults with metastatic pancreatic adenocarcinoma who have undergone at least one prior treatment. The recommendation, part of EMA's Cancer Medicines Pathfinder project, addresses a significant unmet medical need for patients facing limited treatment options and a poor prognosis.